Verition Fund Management’s ImmunityBio IBRX Stock Holding History

Verition Fund Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$248K	Buy	+28,280	New	+$214K	﹤0.01%	1796
2026 Q1	–	Sell	-77,118	Closed	-$528K	–	2880
2025 Q4	$153K	Sell	77,118 -141,063	-65%	-$320K	﹤0.01%	3243
2025 Q3	$537K	Sell	218,181 -27,620	-11%	-$71.1K	﹤0.01%	2983
2025 Q2	$649K	Sell	245,801 -581,238	-70%	-$1.56M	﹤0.01%	2773
2025 Q1	$2.49M	Buy	827,039 +776,709	+1,543%	+$2.35M	0.01%	1419
2024 Q4	$129K	Sell	50,330 -43,940	-47%	-$183K	﹤0.01%	3053
2024 Q3	$351K	Buy	94,270 +53,607	+132%	+$248K	﹤0.01%	2545
2024 Q2	$257K	Buy	+40,663	New	+$268K	﹤0.01%	2440
2023 Q4	–	Sell	-84,770	Closed	-$143K	–	2494
2023 Q3	$143K	Buy	+84,770	New	+$170K	﹤0.01%	2062
2023 Q2	–	Sell	-13,625	Closed	-$24.8K	–	2360
2023 Q1	$24.8K	Buy	+13,625	New	+$42.4K	﹤0.01%	1998

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management's IBRX Position: Q2 2026 in Review

Verition Fund Management opened a new position in ImmunityBio (IBRX) in Q2 2026: 28,280 shares worth $248K. The stake represents ﹤0.01% of the portfolio and ranks #1796 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in IBRX as recently as Q4 2025.

Verition Fund Management first reported a position in IBRX in Q1 2023 and has held it in 10 quarters since. The position peaked at $2.49M in Q1 2025. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Verition Fund Management held 28,280 shares of ImmunityBio worth $248K as of Q2 2026.
ImmunityBio was a new Verition Fund Management position in Q2 2026.
ImmunityBio made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1796 holding.
Verition Fund Management first reported a position in ImmunityBio in Q1 2023 and has held it in 10 quarters since.
Verition Fund Management's ImmunityBio position peaked at $2.49M in Q1 2025.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.